Trial Profile
A study to evaluate the safety of Nivolumab in elderly patients with previously treated non-small cell lung cancer
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2019
Price :
$35
*
At a glance
- Drugs Nivolumab (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- 12 Feb 2019 Status changed from recruiting to discontinued.
- 23 May 2016 New trial record